Early intravenous landiolol to limit heart muscle damage after STEMI
Official title: The Impact of Sympathetic Drive Control With Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction
Run by Aristotle University Of Thessaloniki · NCT07293832 · Data updated 2026-11-12
This study tries early IV landiolol versus standard oral beta-blockers to see if it reduces the amount of heart muscle damage in adults with STEMI who undergo primary PCI.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Aristotle University Of Thessaloniki Academic / other |
| Locations | 1 site (Thessaloniki, Thessaloniki) |
| Status | Recruiting |
| Started | November 13, 2024 |
| Main results expected | June 2026 |
| Study ends | August 2026 |
| Registry record updated | December 19, 2025 |
| Trial ID | NCT07293832 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–80 years old with ST-elevation ≥2 mm in contiguous leads presenting within 12 hours and scheduled for primary PCI who are not on chronic beta-blockers and can give informed consent.
✕Probably not a fit
Patients with prior myocardial infarction, chronic beta-blocker use, hemodynamic instability (low blood pressure, bradycardia, high Killip class), advanced AV block, or bronchospasm are unlikely to be eligible or to benefit from this approach in this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective observational cohort enrolling adults with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention who receive either early intravenous landiolol or standard oral β-blocker therapy. Treatment choice is made by the attending cardiologist per current ESC guidance rather than by random assignment. Final infarct size will be measured by cardiac magnetic resonance imaging, and comparisons will adjust for baseline clinical differences. Because the design is nonrandomized, results will show associations and may be confounded by treatment selection.
Why it matters
Potential benefit: If successful, early IV landiolol could reduce infarct size after STEMI and help preserve heart function.
How similar studies have gone: Early IV beta-blocker approaches (for example, IV metoprolol in METOCARD-CNIC) have shown reduced infarct size in some studies but results across trials are mixed and landiolol itself is less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 80 years * Patients with electrocardiogram showing ST-segment elevation ≥2 mm in 2 or more contiguous leads for more than 30 minutes * Estimated time from symptom onset to reperfusion ≤12 hours * Patients scheduled to undergo primary angioplasty * Patients who have signed a consent form Exclusion Criteria: * Patients receiving chronic medication with beta-adrenergic blockers * Patients with a previous myocardial infarction * Persistent systolic blood pressure \<90 mmHg * Persistent heart rate \<55 beats per minute * Patients with Killip class III (acute pulmonary edema) or IV (cardiogenic shock) on initial examination * 12-lead electrocardiogram with PR interval \>200 milliseconds * 12-lead electrocardiogram showing second- or third-degree atrioventricular block * Bronchospasm requiring bronchodilator treatment * Possible pregnancy or postpartum period * Inability or refusal to sign the consent form
Where it's running
-
Hippokration General Hospital of Thessaloniki
Thessaloniki, Thessaloniki, Greece Recruiting
Study contacts
- Principal investigator: Nikolaos Fragakis, Professor fo Cardiology, PhD — Aristotle University Of Thessaloniki
- Study coordinator: Athina Nasoufidou, MD, MSc, PhDc
- Email: athinanassi@gmail.com
- Phone: (+30) 2313236344
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Early single antiplatelet therapy after IVUS-guided PCI in ACS
This study tests whether stopping aspirin early and continuing a potent P2Y12 inhibitor alone is safe and effective after IVUS-guided PCI in people with acute coronary syndrome.
-
Drug-coated balloon treatment during emergency angioplasty for STEMI
This registry will try using drug-coated balloons instead of stents during emergency PCI for people with ST-elevation heart attacks to see how the procedure and patient outcomes compare.
-
Retinal OCTA to detect tiny blood vessel problems in people with MINOCA
This project will use a quick retinal OCTA scan to see if tiny blood vessel changes differ in people with MINOCA compared with heart attack patients who have blocked arteries and with healthy volunteers.
-
Long-term changes in left ventricular function after STEMI
We will test whether detailed heart imaging and blood tests can track long-term changes in heart structure and function in people who had a STEMI treated with primary PCI.
-
Targeted look at residual inflammation after a heart attack
This project will test whether the neutrophil-to-lymphocyte ratio (NLR) from the first routine blood draw can help predict risk of death in adults (18–85) after an acute coronary syndrome treated with PCI.
-
Assessing no-reflow in STEMI patients after tirofiban treatment
This study is testing if the drug tirofiban can help prevent no-reflow in patients with a severe heart attack who have had a procedure to open their blocked arteries.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.